Harnessing the Immune System to Fight Cancer: An Interview with Innate Pharma's Mondher Mahjoubi

In this edition of The Onco’Zine Brief Peter Hofland, Ph.D., talks with Mondher Mahjoubi, MD, Chief Executive Officer and Chairman of the Executive Board of Innate Pharma, a clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical needs. The company, based in the South of France, has been a pioneer in the understanding of the biology of natural killer (NK-) cell, and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk, Sanofi, and a multi-products collaboration with AstraZeneca. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.